Timothy Edward Lee has sold IVVD and made no open-market buys since Feb 2026

Timothy Edward Lee, age 51, is the Chief Commercial Officer (CCO) of Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company focused on protection from serious viral infectious diseases, appointed effective June 5, 2024.( He holds a B.S. in Marketing from Saint Joseph’s University and brings over 20 years of experience in biotech and pharma commercialization.(

Lee's career highlights include serving as Head of VP Sales, Commercial Development, and Global Commercial Training at Amylyx Pharmaceuticals from February 2020 to June 2024, where he built launch capabilities leading to the successful rollout of Relyvrio for ALS and generated $390 million in net product revenue in 14 months.( Previously, he drove commercialization strategies for rare disease portfolios at Biohaven Pharmaceuticals (2017–2020) and held key roles at Alexion Pharmaceuticals, Novartis, and Pfizer.( At Invivyd, he oversees commercial efforts amid the launch of PEMGARDA and received a recent equity grant of 675,000 stock options on January 29, 2026.(

Written by Perplexity from public sources.